Linagliptin alleviates fatty liver disease in diabetic db/db mice

doi:10.4239/wjd.v7.i19.534

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 7, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9888)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-14) series, Tables (1-1) series.

Item

Count

PDF

757

WORD

281

HTML

5036

Figures (1-14)

371

Tables (1-1)

323

Sum=6768

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1090

Download

2030

Sum=3120

Nov 15, 2016 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (23)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Diabetes. Nov 15, 2016; 7(19): 534-546
Published online Nov 15, 2016. doi: 10.4239/wjd.v7.i19.534

Table 1 Body weight and plasma biochemical parameters of the placebo-treated and linagliptin-treated db/db mice at the 10th, 14^th and 18^th week of age

Parameters	Placebo group (n = 8)			Linagliptin group (n = 8)
Parameters	10 wk	14 wk	18 wk	10 wk	14 wk	18 wk
Body weight, g	35.1 (25.6-47.7)	33.2 (24.6-50.9)	37.3 (27.3-51.6)	37.6 (34.5-44.2)	39.9 (30.0-42.3)	41.7 (31.5-45.0)
Glucose, mg/dL	637 (549-678)	579 (551-671)	610 (506-683)	651 (631-693)	588 (520-640)	625 (601-646)
Triglycerides, mg/dL	415 (209-510)	324 (209-336)	316 (149-555)	385 (262-637)	279 (251-315)	391 (238-480)
Total cholesterol, mg/dL	129 (94-156)	100 (39-140)	131 (22-156)	112 (28-132)	104 (24-124)	71 (18-120)
ALT, U/L	132 (105-375)	126 (72-369)	170 (69-306)	146 (84-255)	185 (118-225)	203 (80-294)
GGT, U/L	16.7 (8.2-28.1)	13 (8.5-25.1)	14.6 (10.5-16.5)	14.4 (8.9-18.7)	12.5 (7.1-22)	13.6 (10.5-22.7)

Data are shown as the medians, minimal and maximal values. No significant differences in the variables in both groups at week 10 and 18 (Wilcoxon signed rank test, all P > 0.05). The differences between groups are not significant at week 10, 14 and 18 (U-test, all P > 0.05). ALT: Alanine aminotransferase; GGT: Gamma-glutamyl transpeptidase.

Citation: Michurina SV, Ishenko IJ, Klimontov VV, Archipov SA, Myakina NE, Cherepanova MA, Zavjalov EL, Koncevaya GV, Konenkov VI. Linagliptin alleviates fatty liver disease in diabetic db/db mice. World J Diabetes 2016; 7(19): 534-546
URL: https://www.wjgnet.com/1948-9358/full/v7/i19/534.htm
DOI: https://dx.doi.org/10.4239/wjd.v7.i19.534